Susquehanna International Group LLP Buys 154,978 Shares of Sotera Health Company $SHC

Susquehanna International Group LLP increased its stake in shares of Sotera Health Company (NASDAQ:SHC) by 304.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,943 shares of the company’s stock after purchasing an additional 154,978 shares during the quarter. Susquehanna International Group LLP owned approximately 0.07% of Sotera Health worth $3,655,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its stake in shares of Sotera Health by 10.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,204 shares of the company’s stock worth $127,000 after buying an additional 705 shares during the last quarter. Strs Ohio increased its holdings in shares of Sotera Health by 17.4% during the fourth quarter. Strs Ohio now owns 4,895 shares of the company’s stock worth $86,000 after buying an additional 727 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of Sotera Health by 6.0% in the 4th quarter. Federated Hermes Inc. now owns 16,676 shares of the company’s stock valued at $294,000 after acquiring an additional 944 shares during the last quarter. First Citizens Bank & Trust Co. lifted its stake in shares of Sotera Health by 1.5% in the 4th quarter. First Citizens Bank & Trust Co. now owns 66,266 shares of the company’s stock valued at $1,169,000 after acquiring an additional 970 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Sotera Health by 1.7% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 64,993 shares of the company’s stock valued at $1,146,000 after acquiring an additional 1,061 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

Sotera Health Stock Performance

Shares of Sotera Health stock opened at $19.27 on Monday. The stock has a market cap of $5.50 billion, a price-to-earnings ratio of 33.81 and a beta of 1.77. Sotera Health Company has a twelve month low of $13.09 and a twelve month high of $19.85. The company’s fifty day moving average is $18.12 and its 200 day moving average is $16.40. The company has a quick ratio of 2.55, a current ratio of 2.80 and a debt-to-equity ratio of 3.33.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.02. The business had revenue of $321.38 million during the quarter, compared to analyst estimates of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.Sotera Health’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period last year, the company earned $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Sell-side analysts forecast that Sotera Health Company will post 0.86 EPS for the current year.

Insider Transactions at Sotera Health

In related news, insider Michael P. Rutz sold 150,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $18.84, for a total value of $2,826,000.00. Following the sale, the insider directly owned 334,279 shares in the company, valued at $6,297,816.36. This represents a 30.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the sale, the chairman directly owned 3,969,393 shares of the company’s stock, valued at $73,433,770.50. This represents a 17.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,294,515 shares of company stock valued at $23,999,528 over the last 90 days. 15.36% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Barclays boosted their price objective on Sotera Health from $19.00 to $22.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday. UBS Group set a $19.00 price target on Sotera Health in a report on Wednesday, June 24th. The Goldman Sachs Group began coverage on Sotera Health in a research note on Friday, June 5th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Sotera Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Sotera Health currently has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Sotera Health Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.